xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05962606</url>
    </required_header>
    <id_info>
      <org_study_id>S-D21-C300</org_study_id>
      <nct_id>NCT05962606</nct_id>
    </id_info>
    <brief_title>Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.</brief_title>
    <official_title>An Exploratory, Multi-Centre, Interventional, Prospective, Randomised, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of AON-D21 in Patients With Severe Community-Acquired Pneumonia.</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Aptarion Biotech AG</agency>
        <agency_class>Industry</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Aptarion Biotech AG</source>
    <oversight_info>
      <has_dmc>Yes</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        The goal of this clinical trial is to compare the safety and efficacy of AON-D21 versus&#xD;
        placebo, both on top of standard of care, in patients with severe community acquired&#xD;
        pneumonia admitted to ICU (or similar unit). The main questions to answer are:&#xD;
  &#xD;
          -  The safety and tolerability of AON-D21 vs placebo.&#xD;
  &#xD;
          -  The efficacy of AON-D21vs placebo.&#xD;
  &#xD;
          -  The pharmacokinetics of AON-D21.&#xD;
  &#xD;
          -  The pharmacodynamics of AON D21.&#xD;
  &#xD;
          -  To identify biomarkers for patient stratification and analyses in future trials.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        This clinical trial will enroll 100 participants, randomized 2:1 (AON-D21:placebo).&#xD;
  &#xD;
        Participants diagnosed with severe community-acquired pneumonia of bacterial or viral origin&#xD;
        requiring admission to an intensive care unit or similar setting, will receive either AON-D21&#xD;
        or placebo intravenous infusions for up to 10 days.&#xD;
  &#xD;
        In addition, participants will receive standard of care as per local guidelines.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">October 30, 2023</start_date>
    <completion_date type="Anticipated">June 30, 2025</completion_date>
    <primary_completion_date type="Anticipated">May 30, 2025</primary_completion_date>
    <phase>Phase 2</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <intervention_model_description>Multi-center, interventional, randomized, double-blind, placebo-controlled study.</intervention_model_description>
      <primary_purpose>Treatment</primary_purpose>
      <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
      <masking_description>Placebo-controlled</masking_description>
    </study_design_info>
    <primary_outcome>
      <measure>Incidence of Treatment-Emergent Adverse Events.</measure>
      <time_frame>28 days.</time_frame>
      <description>To evaluate the safety and tolerability of AON-D21 versus placebo, including the frequency, severity, and relatedness to study drug of serious and non-serious treatment-emergent adverse events (TEAEs) until Day 28.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Efficacy-no longer requiring respiratory support.</measure>
      <time_frame>28 days.</time_frame>
      <description>Comparing AON-D21 vs placebo on time to no longer requiring respiratory support (defined as high-flow oxygen (HFO) ≥ 30 L/min with FiO2 ≥ 30%), non-invasive mechanical ventilation (NIV), invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) within 28 days.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Efficacy-no longer requiring any organ support.</measure>
      <time_frame>28 days.</time_frame>
      <description>Comparing AON-D21 vs placebo on time no longer requiring any organ support within 28 days.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Efficacy-time to improvement.</measure>
      <time_frame>28 days.</time_frame>
      <description>Comparing AON-D21 vs placebo on time to improvement (defined as a de-escalation in respiratory support) within 28 days.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Efficacy-mean change in SaO2/FiO2 ratio.</measure>
      <time_frame>7 days.</time_frame>
      <description>Comparing AON-D21 vs placebo on mean change in SaO2/FiO2 ratio from Day 1 (Baseline) to Day 7.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Efficacy-organ support-free days.</measure>
      <time_frame>28 days.</time_frame>
      <description>Comparing AON-D21 vs placebo on organ support-free days until Day 28.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Efficacy-invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO)-free days.</measure>
      <time_frame>28 days.</time_frame>
      <description>Comparing AON-D21 vs placebo on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO)-free days until Day 28.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Efficacy-respiratory support-free days.</measure>
      <time_frame>28 days.</time_frame>
      <description>Comparing AON-D21 vs placebo on respiratory support-free days until Day 28.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Efficacy-all-cause mortality.</measure>
      <time_frame>28 days.</time_frame>
      <description>Comparing AON-D21 vs placebo on all-cause mortality up to Day 28.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Efficacy-all-cause mortality.</measure>
      <time_frame>60 days.</time_frame>
      <description>Comparing AON-D21 vs placebo on all-cause mortality up to Day 60.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>AUC of AON-D21.</measure>
      <time_frame>10 days.</time_frame>
      <description>Area under the concentration-time curve (AUC) over the dosing interval at steady state (AUC0-tau).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Cmax of AON-D21.</measure>
      <time_frame>10 days.</time_frame>
      <description>Maximum concentration at steady state (Cmax)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Cav of AON-D21.</measure>
      <time_frame>10 days.</time_frame>
      <description>Average drug concentration at steady state (Cav).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Ctrough of AON-D21.</measure>
      <time_frame>10 days.</time_frame>
      <description>Trough concentrations (Ctrough).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Tmax of AON-D21.</measure>
      <time_frame>10 days.</time_frame>
      <description>Time of maximum concentration at steady state (Tmax).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Half-life of AON-D21.</measure>
      <time_frame>12 days.</time_frame>
      <description>Terminal half-life at steady state (t1/2).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Accumulation of AON-D21.</measure>
      <time_frame>10 days.</time_frame>
      <description>Accumulation ratio for Cmax.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Clearance of AON-D21.</measure>
      <time_frame>12 days.</time_frame>
      <description>Clearance (CL).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Volume of distribution of AON-D21.</measure>
      <time_frame>12 days.</time_frame>
      <description>Volume of distribution (Vz).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>C5a inhibition with AON-D21.</measure>
      <time_frame>12 days.</time_frame>
      <description>To determine the C5a inhibition capacity of AON-D21 by measuring active C5a in blood using a cell-based assay.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Procalcitonin's measurement.</measure>
      <time_frame>12 days.</time_frame>
      <description>Evolution of procalcitonin over time.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Ferritin's measurement.</measure>
      <time_frame>12 days.</time_frame>
      <description>Evolution of ferritin over time.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>IL-6's measurement.</measure>
      <time_frame>12 days.</time_frame>
      <description>Evolution of IL-6 over time.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>C5a's measurement</measure>
      <time_frame>12 days.</time_frame>
      <description>Evolution of C5a over time.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>sC5b-9's measurement.</measure>
      <time_frame>12 days.</time_frame>
      <description>Evolution of sC5b-9 over time.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Neutrophil elastase's measurement.</measure>
      <time_frame>12 days.</time_frame>
      <description>Evolution of neutrophil elastase over time.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>D-dimer's measurement.</measure>
      <time_frame>12 days.</time_frame>
      <description>Evolution of D-dimer over time.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Pro-Adrenomedullin's measurement.</measure>
      <time_frame>12 days.</time_frame>
      <description>Evolution of Pro-Adrenomedullin over time.</description>
    </secondary_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Anticipated">100</enrollment>
    <condition>Community-acquired Pneumonia</condition>
    <arm_group>
      <arm_group_label>AON-D21 plus Standard of Care</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Sterile liquid formulation of AON-D21 in 4% mannitol + 0.05% EDTA in glass vials. It will be administered intravenously, for up to 10 days plus Standard of Care therapy for severe community-acquired pneumonia as per local guidelines.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Placebo plus Standard of Care</arm_group_label>
      <arm_group_type>Placebo Comparator</arm_group_type>
      <description>Sterile liquid formulation of 5% glucose solution in matched glass vials with a 1.5 mL fill volume. It will be administered intravenously, for up to 10 days plus Standard of Care therapy for severe community-acquired pneumonia as per local guidelines.</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>AON-D21</intervention_name>
      <description>AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.</description>
      <arm_group_label>AON-D21 plus Standard of Care</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Placebo</intervention_name>
      <description>Sterile liquid formulation of 5% glucose solution in matched glass vials with a 1.5 mL fill volume.</description>
      <arm_group_label>Placebo plus Standard of Care</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Community-acquired pneumonia, confirmed or suspected of bacterial or viral origin.&#xD;
  &#xD;
            -  Admitted to an ICU (or similar unit).&#xD;
  &#xD;
            -  Requiring respiratory support by HFO ≥ 30 L/min with FiO2 ≥ 30% or NIV or IMV or ECMO.&#xD;
  &#xD;
            -  CRP ≥ 50 mg/L.&#xD;
  &#xD;
            -  PaO2/FiO2 ratio ≤ 300 mmHg.&#xD;
  &#xD;
            -  Treatment initiation no more than 48 h after initiation of respiratory support (HFO ≥&#xD;
               30 L/min with FiO2 ≥ 30%, NIV, IMV or ECMO).&#xD;
  &#xD;
            -  Written informed consent.&#xD;
  &#xD;
            -  Age ≥ 18 years to ≤ 85 years.&#xD;
  &#xD;
            -  Body mass index ≥ 17.5 kg/m² and ≤ 40 kg/m².&#xD;
  &#xD;
            -  For female participants of childbearing potential, agreement to use dual methods of&#xD;
               contraception until Day 60.&#xD;
  &#xD;
            -  For male participants with female partners of childbearing potential, agreement to use&#xD;
               barrier method of contraception until Day 60 and to refrain from donating sperm during&#xD;
               the study and for 3 months after the last infusion.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Refractory septic shock.&#xD;
  &#xD;
            -  Not expected to survive 72 hours.&#xD;
  &#xD;
            -  Hospital-acquired or ventilator-associated pneumonia or known or suspected pneumonia&#xD;
               due to aspiration or other physical injury or trauma or tuberculosis.&#xD;
  &#xD;
            -  Known or suspected hypersensitivity to AON-D21 or any components of the formulation&#xD;
               used (e.g., PEG, mannitol or EDTA) or a history of clinically relevant allergy&#xD;
               requiring continuous treatment, or of anaphylaxis.&#xD;
  &#xD;
            -  Known fibrotic lung disease, bronchiectasis or any other known severe chronic&#xD;
               respiratory disease.&#xD;
  &#xD;
            -  Active malignant disease.&#xD;
  &#xD;
            -  Factors other than a pathogen suspected or confirmed to be causative for the&#xD;
               respiratory insufficiency.&#xD;
  &#xD;
            -  Hepatocellular injury defined by an ALT or AST value ≥ 3 times the ULN. Known acute or&#xD;
               chronic liver disease with Child-Pugh C (See Appendix 13.6.2).&#xD;
  &#xD;
            -  Any medical disease or condition that, in the opinion of the investigator(s),&#xD;
               compromises the participant's safety or compromises the interpretation of the results.&#xD;
  &#xD;
            -  Receiving chronic immunosuppressive therapy in relevant doses.&#xD;
  &#xD;
            -  Known immunodeficiency disease/condition.&#xD;
  &#xD;
            -  Nursing and pregnant women (defined as the state after conception until the&#xD;
               termination of gestation, screened in all women of child-bearing potential with a&#xD;
               chorionic gonadotrophin (hCG) blood test (local laboratory).&#xD;
  &#xD;
            -  Current or recent participation in an investigational trial.&#xD;
  &#xD;
            -  Systemic treatment with any complement inhibitor.&#xD;
  &#xD;
            -  Known complement deficiency.&#xD;
  &#xD;
            -  Unlikely to remain at the investigational site beyond 96 h.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>85 Years</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Martin Witzenrath, MD</last_name>
      <role>Principal Investigator</role>
      <affiliation>Critical Care Medicine. Charité Universitätsmedizin Berlin</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Antonio Perez, MD</last_name>
      <phone>+49-30-959 982-133</phone>
      <email>perez@aptarion.com</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Axel Vater, PhD</last_name>
      <phone>+49-30-959 982-133</phone>
      <email>vater@aptarion.com</email>
    </overall_contact_backup>
    <verification_date>July 2023</verification_date>
    <study_first_submitted>July 17, 2023</study_first_submitted>
    <study_first_submitted_qc>July 25, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">July 27, 2023</study_first_posted>
    <last_update_submitted>July 25, 2023</last_update_submitted>
    <last_update_submitted_qc>July 25, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">July 27, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>Pneumonia</keyword>
    <keyword>Community-acquired</keyword>
    <keyword>Severe</keyword>
    <keyword>Bacterial</keyword>
    <keyword>Viral</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Pneumonia</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05962606
  org study id: S-D21-C300
  nct id: NCT05962606
  lead sponsor: 
  has dmc: Yes
  is fda regulated drug: No
  is fda regulated device: No
  The goal of this clinical trial is to compare the safety and efficacy of AON-D21 versus
        placebo, both on top of standard of care, in patients with severe community acquired
        pneumonia admitted to ICU (or similar unit). The main questions to answer are:
  
          -  The safety and tolerability of AON-D21 vs placebo.
  
          -  The efficacy of AON-D21vs placebo.
  
          -  The pharmacokinetics of AON-D21.
  
          -  The pharmacodynamics of AON D21.
  
          -  To identify biomarkers for patient stratification and analyses in future trials.
  This clinical trial will enroll 100 participants, randomized 2:1 (AON-D21:placebo).
  
        Participants diagnosed with severe community-acquired pneumonia of bacterial or viral origin
        requiring admission to an intensive care unit or similar setting, will receive either AON-D21
        or placebo intravenous infusions for up to 10 days.
  
        In addition, participants will receive standard of care as per local guidelines.
  allocation: Randomized
  intervention model: Parallel Assignment
  intervention model description: Multi-center, interventional, randomized, double-blind, placebo-controlled study.
  primary purpose: Treatment
  masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  masking description: Placebo-controlled
  measure: Incidence of Treatment-Emergent Adverse Events.
  time frame: 28 days.
  description: To evaluate the safety and tolerability of AON-D21 versus placebo, including the frequency, severity, and relatedness to study drug of serious and non-serious treatment-emergent adverse events (TEAEs) until Day 28.
  measure: Efficacy-no longer requiring respiratory support.
  time frame: 28 days.
  description: Comparing AON-D21 vs placebo on time to no longer requiring respiratory support (defined as high-flow oxygen (HFO) ≥ 30 L/min with FiO2 ≥ 30%), non-invasive mechanical ventilation (NIV), invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) within 28 days.
  measure: Efficacy-no longer requiring any organ support.
  time frame: 28 days.
  description: Comparing AON-D21 vs placebo on time no longer requiring any organ support within 28 days.
  measure: Efficacy-time to improvement.
  time frame: 28 days.
  description: Comparing AON-D21 vs placebo on time to improvement (defined as a de-escalation in respiratory support) within 28 days.
  measure: Efficacy-mean change in SaO2/FiO2 ratio.
  time frame: 7 days.
  description: Comparing AON-D21 vs placebo on mean change in SaO2/FiO2 ratio from Day 1 (Baseline) to Day 7.
  measure: Efficacy-organ support-free days.
  time frame: 28 days.
  description: Comparing AON-D21 vs placebo on organ support-free days until Day 28.
  measure: Efficacy-invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO)-free days.
  time frame: 28 days.
  description: Comparing AON-D21 vs placebo on invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO)-free days until Day 28.
  measure: Efficacy-respiratory support-free days.
  time frame: 28 days.
  description: Comparing AON-D21 vs placebo on respiratory support-free days until Day 28.
  measure: Efficacy-all-cause mortality.
  time frame: 28 days.
  description: Comparing AON-D21 vs placebo on all-cause mortality up to Day 28.
  measure: Efficacy-all-cause mortality.
  time frame: 60 days.
  description: Comparing AON-D21 vs placebo on all-cause mortality up to Day 60.
  measure: AUC of AON-D21.
  time frame: 10 days.
  description: Area under the concentration-time curve (AUC) over the dosing interval at steady state (AUC0-tau).
  measure: Cmax of AON-D21.
  time frame: 10 days.
  description: Maximum concentration at steady state (Cmax)
  measure: Cav of AON-D21.
  time frame: 10 days.
  description: Average drug concentration at steady state (Cav).
  measure: Ctrough of AON-D21.
  time frame: 10 days.
  description: Trough concentrations (Ctrough).
  measure: Tmax of AON-D21.
  time frame: 10 days.
  description: Time of maximum concentration at steady state (Tmax).
  measure: Half-life of AON-D21.
  time frame: 12 days.
  description: Terminal half-life at steady state (t1/2).
  measure: Accumulation of AON-D21.
  time frame: 10 days.
  description: Accumulation ratio for Cmax.
  measure: Clearance of AON-D21.
  time frame: 12 days.
  description: Clearance (CL).
  measure: Volume of distribution of AON-D21.
  time frame: 12 days.
  description: Volume of distribution (Vz).
  measure: C5a inhibition with AON-D21.
  time frame: 12 days.
  description: To determine the C5a inhibition capacity of AON-D21 by measuring active C5a in blood using a cell-based assay.
  measure: Procalcitonin's measurement.
  time frame: 12 days.
  description: Evolution of procalcitonin over time.
  measure: Ferritin's measurement.
  time frame: 12 days.
  description: Evolution of ferritin over time.
  measure: IL-6's measurement.
  time frame: 12 days.
  description: Evolution of IL-6 over time.
  measure: C5a's measurement
  time frame: 12 days.
  description: Evolution of C5a over time.
  measure: sC5b-9's measurement.
  time frame: 12 days.
  description: Evolution of sC5b-9 over time.
  measure: Neutrophil elastase's measurement.
  time frame: 12 days.
  description: Evolution of neutrophil elastase over time.
  measure: D-dimer's measurement.
  time frame: 12 days.
  description: Evolution of D-dimer over time.
  measure: Pro-Adrenomedullin's measurement.
  time frame: 12 days.
  description: Evolution of Pro-Adrenomedullin over time.
  arm group label: AON-D21 plus Standard of Care
  arm group type: Experimental
  description: Sterile liquid formulation of AON-D21 in 4% mannitol + 0.05% EDTA in glass vials. It will be administered intravenously, for up to 10 days plus Standard of Care therapy for severe community-acquired pneumonia as per local guidelines.
  arm group label: Placebo plus Standard of Care
  arm group type: Placebo Comparator
  description: Sterile liquid formulation of 5% glucose solution in matched glass vials with a 1.5 mL fill volume. It will be administered intravenously, for up to 10 days plus Standard of Care therapy for severe community-acquired pneumonia as per local guidelines.
  intervention type: Drug
  intervention name: AON-D21
  description: AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
  arm group label: AON-D21 plus Standard of Care
  intervention type: Drug
  intervention name: Placebo
  description: Sterile liquid formulation of 5% glucose solution in matched glass vials with a 1.5 mL fill volume.
  arm group label: Placebo plus Standard of Care
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: 85 Years
  healthy volunteers: No
  last name: Martin Witzenrath, MD
  role: Principal Investigator
  affiliation: Critical Care Medicine. Charité Universitätsmedizin Berlin
  last name: Antonio Perez, MD
  phone: +49-30-959 982-133
  email: perez@aptarion.com
  last name: Axel Vater, PhD
  phone: +49-30-959 982-133
  email: vater@aptarion.com
  responsible party type: Sponsor
  mesh term: Pneumonia
  sharing ipd: No